Halozyme starts trial with Enhanze technology

By Elaine Rigoli

Tampa, Fla., Aug. 8 - Halozyme Therapeutics, Inc. has dosed the first three patients in a clinical trial of Enhanze technology, the company's enzyme-based drug-delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20), intended in this trial to enhance the absorption of a representative large molecule protein therapeutic.

"The initiation of this clinical trial takes us another step closer to further developing the full potential of the human recombinant form of hyaluronidase. If rHuPH20 can be shown to enhance the absorption of large molecule therapeutics and confer benefit either by improved bioavailability, time to absorption, and/or reduced side effects, this method of drug administration may open up new strategies to treating patients with regard to doses administered, dosing intervals, patient tolerability, patient convenience, and health economics," said Richard C. Yocum, vice president of clinical development and medical affairs, in a statement.

Halozyme is a biopharmaceutical company located in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.